MPS Limited on Monday said it has successfully completed the acquisition of 100% stake in Unbound Medicine, Inc., USA, through its wholly-owned subsidiary MPS North America LLC, for a total consideration of $16.5 million.
The company said the transaction was completed pursuant to the Stock Purchase Agreement (SPA) executed on January 30, 2026, and after fulfillment of all customary closing conditions.
The acquisition consideration, subject to standard adjustments, has been fully paid in accordance with the terms of the SPA and related transaction documents. With the completion of the transaction, Unbound Medicine has become a wholly-owned step-down subsidiary of MPS Limited.
MPS had earlier disclosed the proposed acquisition on January 30, 2026, followed by a separate disclosure on February 4, 2026, outlining the funding arrangements for the deal. Unbound Medicine is a US-based provider of digital medical knowledge and clinical decision-support solutions, offering mobile and web-based reference tools for healthcare professionals.
The acquisition is expected to strengthen MPS’s presence in the global healthcare content and technology space, particularly in high-value medical reference platforms. The company said the acquisition aligns with its long-term strategy of expanding its healthcare and life sciences offerings and deepening its footprint in the North American market through technology-led platforms and intellectual property assets.